Drugs / STUP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06922890 | Jul 2025 → Dec 2026 expected | spinal cord injury | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STUP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06922890 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “This study aim to investigate the safety and exploratory efficacy of STUP-001 which is AAV-based spinal cord injury investigational product.” NCT06922890 ↗ |
| Route | Other | “via the intraparenchymal route into the spinal cord” NCT06922890 ↗ |